Welcome to our dedicated page for iTonic Holdings SEC filings (Ticker: ITOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
iTonic Holdings Ltd filings document foreign-issuer current reports on its brachytherapy healthcare-solutions business, corporate events and listed-company status. The company's Form 6-K disclosures include press-release exhibits, Nasdaq minimum bid price compliance matters, and descriptions of its operating subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., and lead treatment-planning product.
The filing record also covers material-event disclosures, material agreements, capital-structure matters, governance topics, and operating and financial results. These disclosures connect the company's public reporting to its Class A ordinary shares, healthcare-technology operations and corporate obligations as a listed issuer.
iTonic Holdings Ltd reported a board change and disclosed the standard terms of its director agreement. On January 22, 2026, independent director Yun Fai Wong resigned from the board for personal reasons, with the company stating there was no disagreement regarding its operations, policies or practices. The board simultaneously appointed Bin Wu as a new independent director and as a member of the Audit, Corporate Governance and Nominating, and Compensation Committees, and named him chair of the Corporate Governance and Nominating Committee.
iTonic notes that Bin Wu graduated from Wuhan University and holds an MBA from Duke University, and believes he meets Nasdaq and SEC independence standards. The filing includes a form of director agreement and indemnification agreement, outlining a fixed board term, quarterly cash fees, annual option grants under a share incentive plan, confidentiality and non-solicitation covenants, D&O insurance coverage, and Cayman Islands governing law.